In Vitro and In Vivo Assessment of Metabolic Drug Interaction Potential of Dutasteride with Ketoconazole
Open Access
- 11 December 2019
- journal article
- research article
- Published by MDPI AG in Pharmaceutics
- Vol. 11 (12) , 673
Abstract
Dutasteride (DUT) is a selective, potent, competitive, and irreversible inhibitor of both type-1 and type-2 5α-reductase (5AR) commonly used in the treatment of benign prostatic hyperplasia and androgenetic alopecia. In the present study, we developed a simple and sensitive high-performance liquid chromatography with fluorescence detection (HPLC-FL) method for simultaneous determination of DUT and its major active metabolite, 6β-hydroxydutasteride (H-DUT). Next, the pharmacokinetic interactions of DUT with ketoconazole (KET), a potent CYP3A inhibitor, were comprehensively investigated. In vivo rat intravenous and oral studies revealed that the pharmacokinetics of DUT and H-DUT were significantly altered by the co-administration of KET. Furthermore, the in vitro microsomal metabolism, blood distribution, and protein-binding studies suggest that the altered pharmacokinetics of DUT could be attributed primarily to the inhibition of the DUT metabolism by KET. To the best of our knowledge, this is the first study to show the drug interaction potential of DUT with azole antifungal drugs including KET, together with a newly developed HPLC-FL method for the simultaneous quantification of DUT and H-DUT.Keywords
Funding Information
- National Research Foundation of Korea (NRF-2017R1D1A3B03030252, 2018R1A2A3075248)
This publication has 34 references indexed in Scilit:
- In vitro–in vivoextrapolation (IVIVE) for predicting human intestinal absorption and first-pass elimination of drugs: principles and applicationsDrug Development and Industrial Pharmacy, 2013
- A simple and sensitive HPLC fluorescence method for determination of tadalafil in mouse plasmaJournal of Chromatography B, 2010
- Investigation of the Rate-Determining Process in the Hepatic Elimination of HMG-CoA Reductase Inhibitors in Rats and HumansDrug Metabolism and Disposition, 2010
- Effect of dutasteride on the expression of hypoxia-inducible factor-1α, vascular endothelial growth factor and microvessel density in rat and human prostate tissueScandinavian Journal of Urology and Nephrology, 2009
- Effects of Cytochrome P450 Inhibitors on the Biotransformation of Fluorogenic Substrates by Adult Male Rat Liver Microsomes and cDNA-Expressed Rat Cytochrome P450 IsoformsToxicological Sciences, 2009
- Antipsychotic-Like Properties of 5-α-Reductase InhibitorsNeuropsychopharmacology, 2008
- DutasterideDrugs, 2008
- Drug Insight: 5α-reductase inhibitors for the treatment of benign prostatic hyperplasiaNature Reviews Endocrinology, 2006
- Androgens and alopeciaMolecular and Cellular Endocrinology, 2002
- Differences in steroid 5α-reductase iso-enzymes expression between normal and pathological human prostate tissueThe Journal of Steroid Biochemistry and Molecular Biology, 1999